Generative AI Deployment to 20,000 Employees: Microsoft Copilot and ChatGPT Enterprise at Amgen

Amgen is a US-based biotechnology company and one of the world leading independent biotechnology firms. In 2023-2025, Amgen undertook a deliberate multi-phase deployment of generative AI tools. The company initially equipped just 300 employees with Microsoft 365 Copilot in late 2023 and scaled to 20,000 users by mid-2024. A year after first deploying Copilot, Amgen began broader use of ChatGPT Enterprise in 2024, citing strong employee preference and positive feedback. Internal surveys confirmed high user satisfaction: scientists and staff found ChatGPT effective for tasks like analyzing data and drafting reports. Amgen deployed its AI governance framework aligned with NIST Trustworthy AI principles, with security and compliance guardrails embedded throughout the process. Amgen tracked adoption through user counts, usage logs, and employee feedback. Amgen CTO and SVP reported daily use of AI tools and integration from the office to the lab. Executives observed that Copilot and ChatGPT helped streamline routine tasks, enabling staff to focus on high-value research and innovation. The company emphasized measured testing supported by security, enabling integration of technology into meaningful workflows. This comprehensive report examines Amgen AI adoption as a case study and situates it within broader industry trends including comparison with Moderna, Pfizer, and Johnson & Johnson.